Prismatic correction in patients affected by age-related macular degeneration.

Maurizio Battaglia Parodi, Lisa Toto, Leonardo Mastropasqua, Marta Depollo, Giuseppe Ravalico

Journal: Clinical rehabilitation 2005;18(7):828-32

PMID: 15573840

Abstract

OBJECTIVE

To evaluate by means of a controlled clinical trial the effectiveness and the tolerance of prismatic correction in improving visual function in patients affected by advanced bilateral age-related macular degeneration.

SETTING

Department of Ophthalmology, Eye Clinic, University of Trieste.

SUBJECTS AND INTERVENTIONS

Each patient underwent an ophthalmologic examination, complete with distance visual acuity measurement using the Standard Early Treatment Diabetic Retinopathy Study chart. Patients were then randomly assigned to the treatment or control group. The treatment group received spectacles lenses with a prismatic correction of low power (5-7 prismatic dioptres) in the better eye.

MAIN MEASURES

Visual acuity was measured at baseline and 1, 90, 180 and 360 days after prescription in both groups.

RESULTS

The treatment group consisted of 14 patients, while the control group was of 14 patients. The prismatic correction was well tolerated in 85.7% of cases. Visual acuity in the treatment group improved mostly at three-month follow-up, with a slight further improvement at the six- and 12-month follow-ups, showing a statistically significant difference in comparison with the control group. No visual acuity improvement was registered in the control group.

CONCLUSION

Monolateral prismatic correction may be considered a viable means to improve visual function in patients affected by bilateral age-related macular degeneration at an advanced stage.

Address: Eye Clinic, University of Trieste, Italy. [email protected]
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.